Association of AFP with Hepatocellular Carcinoma Subtypes
- 1College of Human Medicine, Michigan State University, East Lansing, MI 48824, USA
- 2Department of Medicine, Michigan State University, East Lansing, MI 48824, USA
- 3Department of Surgery, Michigan State University, East Lansing, MI 48823, USA
Abstract
Background/Objectives: Alpha-fetoprotein (AFP) is often elevated in hepatocellular carcinoma (HCC) and has been linked to poor prognosis. Among HCC subtypes, the association is less defined. We aimed to characterize AFP and their association with prognosis for the fibrolamellar, scirrhous, clear-cell, spindle-cell, and pleomorphic subtypes of HCC. Methods: Patients in the National Cancer Database (NCDB) diagnosed with HCC between 1998–2021, including not otherwise specified (NOS), fibrolamellar, scirrhous, clear-cell, spindle-cell, and pleomorphic were included. Elevated AFP was defined as 400 ng/mL or above. Associations between clinical characteristics, including AFP levels, and HCC subtypes were analyzed using two-sample t-test, chi-square, and Fisher exact tests. Survival was assessed using Kaplan–Meier curves with log-rank tests. Results: The study population included 168,470 patients, of which 166,778 (99.0%) were HCC NOS, followed by 872 (0.5%) clear-cell, 417 (0.2%) fibrolamellar, 251 (0.2%) scirrhous, 136 (0.1%) spindle-cell, and 16 (0.01%) pleomorphic. Elevated AFP was highest in the spindle-cell subtype (30.9%), followed by HCC NOS (29.4%), scirrhous (25.1%), clear-cell (23.4%), and fibrolamellar (15.6%) (p < 0.0001). Elevated AFP was significantly different across stage of disease with elevation in 11.9% of fibrolamellar, 6.8% of scirrhous, 35.7% of spindle-cell, 25.2% of clear-cell, and 17.6% of HCC NOS at stage 2; 22.5%, 50%, 33.3%, 28.2%, and 44.2%, respectively at stage 3; and 13.8%, 30.4%, 31.7%, 42.2%, and 53.2%, respectively, at stage 4 (all p < 0.005). Elevated AFP was associated with decreased survival for the fibrolamellar (9.7 months when elevated vs. 39 months when not elevated), scirrhous (3.8 vs. 24.2) and clear-cell (7.2 vs. 25.9) subtypes (p < 0.0001). Conclusions: Elevated AFP is least prevalent for fibrolamellar HCC, including when stratifying by disease stage, though it is associated with worse survival in that population. AFP elevation may offer important prognostic information when rare subtypes are diagnosed.
Related
- Adherencia a la vigilancia del carcinoma hepatocelular y su asociación con el estadio tumoral al diagnóstico: experiencia de un hospital universitario Adherence to Hepatocellular Carcinoma Surveillance and Its Association with Tumor Stage at Diagnosis: Experience at a University Hospital
- Association of steatotic liver disease with long-term oncological outcomes after hepatic resection for hepatocellular carcinoma
- Gilteritinib Suppresses Hepatocellular Carcinoma Cells in Association with Reduced Calpain-1 Expression and Inhibition of STAT3/AKT Signaling
- Association of 5-hydroxytryptamine 3 receptor antagonists with prognosis in patients with advanced hepatocellular carcinoma: A propensity score-matched study
- Association between the preoperative C-reactive protein-albumin-lymphocyte index and prognosis after hepatic resection for hepatocellular carcinoma
BibTeX
@article{rose2026association,
title = {{Association of AFP with Hepatocellular Carcinoma Subtypes}},
author = {Callie Rose and James Hosner and Seung Hwan Chung and Ling Wang and Linda Qu},
journal = {Cancers},
year = {2026},
month = nov,
doi = {10.3390/cancers18213524},
url = {https://www.mdpi.com/2072-6694/18/21/3524},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Association of AFP with Hepatocellular Carcinoma Subtypes
AU - Callie Rose
AU - James Hosner
AU - Seung Hwan Chung
AU - Ling Wang
AU - Linda Qu
PY - 2026
DA - 2026/11/02
JO - Cancers
DO - 10.3390/cancers18213524
UR - https://www.mdpi.com/2072-6694/18/21/3524
AB - Background/Objectives: Alpha-fetoprotein (AFP) is often elevated in hepatocellular carcinoma (HCC) and has been linked to poor prognosis. Among HCC subtypes, the association is less defined. We aimed to characterize AFP and their association with prognosis for the fibrolamellar, scirrhous, clear-cell, spindle-cell, and pleomorphic subtypes of HCC. Methods: Patients in the National Cancer Database (NCDB) diagnosed with HCC between 1998–2021, including not otherwise specified (NOS), fibrolamellar, scirrhous, clear-cell, spindle-cell, and pleomorphic were included. Elevated AFP was defined as 400 ng/mL or above. Associations between clinical characteristics, including AFP levels, and HCC subtypes were analyzed using two-sample t-test, chi-square, and Fisher exact tests. Survival was assessed using Kaplan–Meier curves with log-rank tests. Results: The study population included 168,470 patients, of which 166,778 (99.0%) were HCC NOS, followed by 872 (0.5%) clear-cell, 417 (0.2%) fibrolamellar, 251 (0.2%) scirrhous, 136 (0.1%) spindle-cell, and 16 (0.01%) pleomorphic. Elevated AFP was highest in the spindle-cell subtype (30.9%), followed by HCC NOS (29.4%), scirrhous (25.1%), clear-cell (23.4%), and fibrolamellar (15.6%) (p < 0.0001). Elevated AFP was significantly different across stage of disease with elevation in 11.9% of fibrolamellar, 6.8% of scirrhous, 35.7% of spindle-cell, 25.2% of clear-cell, and 17.6% of HCC NOS at stage 2; 22.5%, 50%, 33.3%, 28.2%, and 44.2%, respectively at stage 3; and 13.8%, 30.4%, 31.7%, 42.2%, and 53.2%, respectively, at stage 4 (all p < 0.005). Elevated AFP was associated with decreased survival for the fibrolamellar (9.7 months when elevated vs. 39 months when not elevated), scirrhous (3.8 vs. 24.2) and clear-cell (7.2 vs. 25.9) subtypes (p < 0.0001). Conclusions: Elevated AFP is least prevalent for fibrolamellar HCC, including when stratifying by disease stage, though it is associated with worse survival in that population. AFP elevation may offer important prognostic information when rare subtypes are diagnosed.
SN - 2072-6694
ER -